Mylan says it won’t testify at a Senate hearing about the EpiPen (MYL)

Heather Bresch Mylan

Mylan won’t be appearing at a November 30 Senate hearing into the EpiPen. 

The hearing, titled “Oversight of the EpiPen Crisis and Settlement: Where is the Federal Government in Looking out for Taxpayers and Patients?” is being held by the Senate Committee on the Judiciary, headed by Senator Chuck Grassley of Iowa. 

“From the stated title of the hearing, we understand that the intended focus of the hearing will be on the Committee’s oversight of government agencies as it relates to a pending matter,” Mylan’s lawyers wrote to Grassley. Citing other agencies declining to testify as well, Mylan declined the invite to testify.  

On October 7, Mylan said it agreed to pay $465 million to the Department of Justice and other government agencies over the way it classified the EpiPen in the Medicaid Drug Rebate Program. 

The DOJ also declined to testify at the hearing, saying that “it hasn’t “agreed to any settlement with any potential party.” 

In other words, Mylan may think it is close to a settlement, but the DOJ won’t publicly back that claim up. It also won’t even admit that it is looking into the matter, even though Mylan has said in SEC filings that it was subpoenaed back in November 2014. 

Naturally, this is frustrating lawmakers. Sen. Elizabeth Warren has already excoriated the DOJ over the figure reported by Mylan, arguing that it’s lower than the law covering this kind of overcharging dictates. 

“It’s hard to understand why the Justice Department won’t testify about allegedly hundreds of  millions of dollars in overcharges to the taxpayers,” Grassley said in a statement regarding the DOJ’s decision. “Accountability requires getting answers about why the overcharges happened and what, if anything, is being done to make sure the taxpayers are repaid for their losses and to keep this from happening again.”

The back-and-forth over Medicaid classification isn’t not the only legal matter Mylan’s facing. The company’s also under investigation generic price collusion, unrelated to the EpiPen, along with a number of other lawsuits listed earlier this month in the company’s 10Q.

SEE ALSO: EpiPen-maker Mylan whiffs on earnings

DON’T MISS: A pharma giant just made a $100 million move into a disease that’s been called ‘one of the next epidemic-level chronic diseases’

Join the conversation about this story »

Mylan says it won’t testify at a Senate hearing about the EpiPen (MYL) syndicated from https://lawpallc.wordpress.com

Advertisements

Author: Tristan Fox

I love to spend my weekends roaming around my neighborhood with my bike. I am into promoting online websites related to lawsuits, law tips and lawfirms. In this way I am aiding them in pushing their contents in gaining more leverage for the power of internet for local lawfirms in and around my area.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s